FDA Opens Comment Docket on VOQUEZNA Exclusivity Fight; Second ANDA Filer Emerges
PHAT is trading near its 52-week low of $5.015 (9.7% above the low) on elevated volume (3.3× avg).
Summary
The FDA opened a public comment docket (deadline November 23, 2026) on the legal fight over VOQUEZNA's exclusivity through May 3, 2032, and a second ANDA filer, Saba, is seeking to consolidate its case with BDR's challenge.
Key Events · Legal and Risk Events · PHAT
-
FDA Opens Public Comment Docket
The FDA established Docket No. FDA-2026-N-13038 to solicit comment on legal and regulatory questions raised by BDR's ANDA litigation over VOQUEZNA.
-
Comment Deadline November 23, 2026
Public comments are due November 23, 2026; Phathom says it will argue that the FDA's June 6, 2025 Citizen Petition decision granting NCE exclusivity through May 3, 2032 was correct.
-
Second ANDA Filer Emerges
Saba Ilac Sanayii Ve Ticaret AS filed a notice in the BDR litigation claiming a pending related case and intends to move to consolidate with BDR's case.
-
Exclusivity Still in Effect
Phathom states the 10-year NCE exclusivity through May 3, 2032 remains in effect; the filing warns the FDA could reconsider or reverse its decision in light of comments.
Analysis · PHAT · Life Sciences
Phathom's entire revenue base is VOQUEZNA, and its protection rests on 10 years of NCE exclusivity running through May 3, 2032. BDR is suing the FDA to overturn that grant, and the FDA has now opened a public docket (FDA-2026-N-13038) inviting comment on the legal questions, with a November 23, 2026 deadline. That converts a private lawsuit into a public proceeding where outside parties can push the FDA to reconsider — the filing itself flags that risk. The new detail is a second purported ANDA filer, Saba, claiming a related case and seeking to consolidate with BDR, which widens the challenge. Nothing has been decided; exclusivity remains in effect, but the path to earlier generic competition now has two challengers and a public comment window.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAT was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.4M. The 52-week trading range was $5.02 to $18.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.